Clinical Trial Detail

NCT ID NCT03036098
Title Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

transitional cell carcinoma

Therapies

Cisplatin + Gemcitabine

Ipilimumab + Nivolumab

Carboplatin + Gemcitabine

Age Groups: adult senior

No variant requirements are available.